Immuneering Corporation announced plans to start a Phase 2 clinical trial testing atebimetinib combined with chemotherapy for anaplastic thyroid cancer (ATC), a fast-progressing cancer with limited treatment options. The trial aims to enroll around 60 patients, including those with BRAF mutations, with IND submission expected by end of 2026 and first dosing targeted for mid-2027. This study could be registrational, potentially offering a new treatment for a cancer type with poor prognosis and urgent unmet needs. Preclinical data supporting this approach will be presented at a major cancer symposium in November 2026.
Immuneering's new Phase 2 trial plans for anaplastic thyroid cancer provide context for health sector activity on Pluang. For readers following the health sector, here is Pluang's market snapshot as of Nov 12, 2026 19:11 WIB: out of 150 priced US health stocks, 91 rose and 53 fell. Notable movers include INO at USD 1.43 with a 3.05% decline and a typical hold time of 41 days, HIMS at USD 20.20 down 2.93% with 24 days hold time, and LLY at USD 1,477.12 up 2.74% with a 94-day hold time. Pluang order activity shows a majority selling trend for INO and HIMS, while LLY has 83% sell orders.
Evaxion, a clinical-stage TechBio company, has released its financial calendar for 2027, outlining important dates for business updates and financial results. Key events include the full year 2026 results on March 4, the Annual General Meeting on Apr...
CollPlant Biotechnologies will change its Nasdaq ticker from CLGN to OPHI starting November 13, 2026, reflecting its strategic shift toward photonic computing through its subsidiary LightSolver. This move highlights CollPlant's focus on developing Li...
Glider has introduced a global investing platform for tokenized stocks that operates permissionlessly, bypassing the SEC's Tokenized Securities Venues (TSVs) which 50 public companies recently rejected. Backed by major investors like a16z and Coinbas...
BofA Securities raised its price target for Royal Caribbean Group to $365, citing strong booking volumes and the company’s goal of adjusted earnings per share around $20 by 2027. The cruise operator expects 4.5% capacity growth next year and has repo...
Tilray Brands announced that its subsidiaries 10 Barrel Brewing, Widmer Brothers Brewing, and Hop Valley Brewing are now the official craft beer partners of the Portland Trail Blazers. This partnership expands the availability of Oregon craft beers a...
